AstraZeneca Pharma India Limited

Goldman Sachs Raises AstraZeneca Target Price to £163 – What It Means for Investors

Goldman Sachs raises AstraZeneca target price to £163, citing strong drug pipeline, strategic partnerships, and resilient earnings—investors should watch upcoming earnings for confirmation.

20/08/2026, 13:10

2 minutes to read

How AstraZeneca Pharma India Balances Lung‑Cancer Wins, Phase‑3 Setbacks, and Rare‑Disease Innovation

Discover how AstraZeneca Pharma India balances lung‑cancer wins, Phase‑3 setbacks, and rare‑disease AI collaborations to stay ahead of rivals and market volatility.

19/08/2026, 03:33

3 minutes to read

AZN: AstraZeneca Pharma India Announces Board & Shareholder Meetings, 2025‑26 Report & Market Snapshot

Explore AstraZeneca Pharma India’s latest governance updates, annual report highlights, and market snapshot—insights for investors and pharma enthusiasts.

06/08/2026, 14:17

2 minutes to read

AZ Pharma India Expands Oncology Reach with $600M EGFR License to Zegfrovy

Discover how AstraZeneca Pharma India’s exclusive Zegfrovy license and new EGFR deal boost its oncology pipeline, unlock $600M upfront, and reshape cancer treatment in India.

14/07/2026, 08:11

4 minutes to read